SS Innovations Surpasses 10,500 Surgeries Performed with the SSi Mantra Surgical Robotic System
Rhea-AI Summary
SS Innovations (Nasdaq: SSII) announced that more than 10,500 cumulative surgeries have been performed using its SSi Mantra surgical robotic system as of April 30, 2026. The tally includes >500 cardiac procedures, 170 telesurgeries, 125 pediatric surgeries, ~2,100 trained physicians, and an installed base of >200 systems across 11 countries.
The milestone highlights multi-specialty adoption and training scale since the SSi Mantra commercial launch in August 2022.
AI-generated analysis. Not financial advice.
Positive
- 10,500+ cumulative surgeries performed
- 200+ installed systems across 11 countries
- 2,100 physicians trained on SSi Mantra
- 170 different procedure types performed
Negative
- None.
News Market Reaction – SSII
On the day this news was published, SSII declined 3.70%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SSII was up about 1.5% while momentum-flagged peers were mixed: AHCO down 13.03% and IART up 5.98%. Broader peers also showed both gains and losses, pointing to stock-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Tech showcase | Positive | -2.8% | New surgical robotic concepts and live SSi Mantra demonstrations at SMRSC 2026. |
| Apr 07 | Conference announcement | Positive | -0.6% | Announcement of hosting SMRSC 2026 with live telesurgeries and demos. |
| Mar 30 | Regulatory approvals | Positive | +0.2% | SSi Mantra regulatory approvals in Colombia, Oman, Sri Lanka and Kenya. |
| Mar 18 | Telesurgery approvals | Positive | +7.2% | Regulatory approval for telesurgeries in Indonesia and the Philippines. |
| Mar 10 | Earnings results | Positive | -5.6% | Strong 2025 revenue growth, margin expansion and improved net loss. |
Recent history shows several instances where positive operational or financial news was followed by negative price reactions, with regulatory and telesurgery approvals more likely to align positively.
Over the last few months, SS Innovations reported strong 2025 growth with revenue up 105.7% to $42.5M, expanding gross margin to 46.0%, and cumulative surgeries reaching 7,885 by year-end. Subsequent updates highlighted telesurgery approvals in Indonesia and the Philippines, multi-country approvals in Colombia, Oman, Sri Lanka and Kenya, and new robotic concepts showcased at SMRSC 2026. Today’s news that SSi Mantra has surpassed 10,500 cumulative surgeries and an installed base above 200 systems builds directly on this utilization and geographic expansion trajectory.
Regulatory & Risk Context
An effective-date pending S-3 shelf filed on 2026-05-01 registers up to $150,000,000 of securities and 5,016,500 resale shares tied to a March 6, 2026 private placement and associated warrants. The company would receive proceeds only upon warrant exercise. The filing indicates significant existing insider voting control and provides flexibility for future capital raises once effective.
Market Pulse Summary
This announcement underscores continued adoption of SSi Mantra, with more than 10,500 cumulative surgeries, over 500 cardiac cases, and an installed base above 200 systems across eleven countries. It follows prior updates on telesurgery approvals and multi-country regulatory clearances, reinforcing a utilization and expansion narrative. Investors may watch how procedure growth translates into revenue and margins and consider the implications of the recently filed $150,000,000 shelf registration for future capital needs.
Key Terms
surgical robotic system technical
telesurgeries medical
installed base technical
AI-generated analysis. Not financial advice.
FORT LAUDERDALE, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that more than 10,500 cumulative surgeries have been successfully performed with the Company’s SSi Mantra surgical robotic system (the “SSi Mantra”). As of April 30, 2026, the cumulative number of multi-specialty procedures completed with the SSi Mantra exceeded 10,500, including more than 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of procedures.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Since the SSi Mantra’s commercial launch in August 2022, we have established a formidable presence in the vast Indian market and expanded our global installed base to more than 200 systems across eleven countries. Reaching 10,500 cumulative surgeries in such a short time span reflects the SSi Mantra’s advanced technology, differentiated features, ease of training, user-friendliness, and clear cost advantages. I extend my gratitude to the growing number of healthcare institutions and surgeons who trust the SSi Mantra to deliver successful outcomes for their patients and thank the SS Innovations team for their unwavering commitment to continuous improvement. Together, we are helping democratize access to world-class surgical robotic care.”
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana Tele Surgeon Console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
